PMC2758365_01
MR images in relation to surgery, radiotherapy, and adjuvant maintenance imatinib and HU therapy
11060_2008_9790_Fig1_HTML.jpg
PMC2758365_01_11060_2008_9790_Fig1_HTML.jpg
Fig1
Because of signs of tumor progression with extensive headache, multiple focal epileptic seizures, and gadolinium enhancement in MRI, further neurosurgical resection was necessary in November 2003 (Figs. 1, 3). The pattern of the gadolinium enhancement also remained unchanged (Figs. 1, 2).
Longitudinal data with MET-PET images and a plot of the time course of MET uptake index and tumor volume. In the last two MET-PET scans plotted, all pixels were below the threshold index of 1.5. Thus, there was no detectable tumor volume
11060_2008_9790_Fig2_HTML.jpg
PMC2758365_01_11060_2008_9790_Fig2_HTML.jpg
Fig2
Despite further resection and combined radiochemotherapy, an increased metabolic pattern could be observed (Fig. 2). The pattern of the gadolinium enhancement also remained unchanged (Figs. 1, 2).
Overview of all therapeutic events and MET-PET imaging since diagnosis of GBM was confirmed
11060_2008_9790_Fig3_HTML.jpg
PMC2758365_01_11060_2008_9790_Fig3_HTML.jpg
Fig3
Because of signs of tumor progression with extensive headache, multiple focal epileptic seizures, and gadolinium enhancement in MRI, further neurosurgical resection was necessary in November 2003 (Figs. 1, 3). After resection, external radiation therapy up to a total dose of 60 Gy with concomitant temozolomide chemotherapy (75 mg per square meter of body-surface area per day, seven days per week from the first to the last day of radiotherapy) was performed from December 2003 to January 2004 (Fig. 3). April 2007 (Fig. 3). Additionally, the patient was treated for symptomatic epilepsy with 600 mg oxcarbazepine, for mood stabilization with 50 mg trimipramine, and for hypothyreoidism with 75 mug levothyroxine per day.